SLC5A2 and diabetes mellitus: The EMPEROR-Reduced and DAPA-HF trials showed that SGLT2 inhibitors treatment reduced the mortality and heart failure hospitalizations in patients with heart failure and a reduced ejection fraction, regardless of the diagnosis of diabetes (McMurray et al., 2019; Packer et al., 2020).